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Abstract 21 
The clinical potential of multipotent mesenchymal stem cells (MSCs) has led to the essential 22 
development of analytical tools such as antibodies against membrane-bound proteins for the 23 
immunophenotypic characterization of human and rodent cells. Such tools are frequently lacking 24 
for emerging large animal models like the sheep that have greater relevance for the study of 25 
human musculoskeletal diseases. The present study identified a set of commercial nonspecies 26 
specific monoclonal antibodies for the immunophenotypic characterization of ovine MSCs. A 27 
protocol combining the less destructive proteolytic activity of accutase and EDTA was initially 28 
developed for the detachment of cells from plastic with minimum loss of cell surface antigens. A 29 
range of commercially available antibodies against human or rodent MSC antigens were then 30 
tested in single and multistain-based assays for their cross-reactivity to bone marrow derived 31 
ovine MSCs. Antibody clones cross-reactive to ovine CD73 (96.9% ± 5.9), CD90 (99.6% ± 0.3), 32 
CD105 (99.1 ± 1.5), CD271 (97.7 ± 2.0), and MHC1 (94.0% ± 7.2) antigens were identified using 33 
previously reported CD29, CD44, and CD166 as positive controls. Multistaining analysis 34 
indicated the colocalization of these antigens on MSCs. Furthermore, antibody clones identified 35 
to cross-react against white blood cell antigens exhibited either negative (CD117 (0.1% ± 0.1)) 36 
or low (MHCII (10.5% ± 16.0); CD31 (14.6% ± 4.2), and CD45 (39.4% ± 31.8)) cross-reactivity 37 
with ovine MSCs. The validation of these antibody clones to sheep MSC antigens is essential 38 
for studies utilizing this large animal model for stem cell-based therapies. © 2016 International 39 
Society for Advancement of Cytometry 40 
  41 
Introduction 42 
Multipotent mesenchymal stem cells (MSCs) have been defined as mononuclear spindle 43 
shaped clonogenic cells capable of tri-lineage differentiation and positive expression of cell 44 
surface markers including CD73, CD90 and CD105 (1).These cells have predominantly been 45 
isolated from bone marrow, based on methods that rely on early tissue culture plastic 46 
adherence, in contrast to the non-adherent hematopoietic stem cells and their related 47 
progenitors (2-3).  There has been considerable interest in the potential clinical usefulness of 48 
these cells to treat diseases where natural healing is dysfunctional or inadequate.  Indeed, both 49 
experimental studies in vitro and more limited clinical case series in large animal models 50 
suggest efficacy although their mechanism of action has not been completely determined (4–7).  51 
Fewer negative studies have been published although there is concern that regenerative 52 
medicine has not delivered as radical a step forward in therapeutic efficiency as originally 53 
promised.  A major limitation to the field has been the diverse methodologies of therapeutic cell 54 
preparations which could explain variable results.  Consequently, the scientific community has 55 
drawn up strict characterisation guidelines for MSC related studies in humans (1), which has 56 
been based on analytical tools such as antibodies against cell membrane receptors.  Because 57 
no single cell surface marker defines an MSC, these guidelines suggest a panel of both positive 58 
and negative markers to evaluate cellular identity.  Furthermore, there is also concern that small 59 
mammal models do not accurately reflect the characteristics of human disease (8), thus 60 
generating incentive for the use of large animal models, such as the horse and sheep, which 61 
bear a closer clinical parallel to man.   Tools to identify cell surface markers in these species is 62 
limited, with early studies showing poor cross-reactivity of rodent-targetted antibodies (9–11).  63 
The advance of regenerative medicine would therefore benefit from immunophenotypic 64 
characterisation of MSCs from these species to enable standardisation and comparison of cell 65 
preparations used both experimentally and clinically.  66 
 67 
The present study aimed to identify non-species specific monoclonal antibodies from 68 
commercial sources with the potential to cross-react with cognate antigens on ovine MSCs to 69 
standardise immunophenotyping for this animal model. The development of antibodies against 70 
novel cell surface markers is a technically elaborate process (12), whereas an alternative 71 
approach using commercially available antibodies for other species has been applied previously 72 
with success in horses (9–11) but only for a limited number of markers in the sheep  (13).  Our 73 
strategy was to test a large number of commercially available antibodies against well 74 
characterised ovine MSCs, and confirm experimentally their cross-reactivity to ovine MSCs.  75 
Materials and methods 76 
Animal work 77 
The study was carried out under approval from the Ethics and Welfare Committee of the Royal 78 
Veterinary College. Adult female English mule sheep were used to obtain bone marrow 79 
aspirates and blood under general anaesthesia.  Briefly, sheep were given intravenous 80 
injections of 2 % xylazine (Rompun; Bayer Healthcare), ketamine (Ketaset; Fort Dodge Animal 81 
Health) and midazolam (Hypnovel; Roche) at doses of 0.1 mg, 2 mg and 2.5 mg respectively 82 
per kg of body mass. Anaesthesia was maintained with ~2% isoflurane gas (IsoFlo, Abbott 83 
Labs) to effect. Bone marrow (BM) was extracted from the iliac crest of the right tuber coxa into 84 
syringes with heparin at a concentration of 100 IU per 1 ml of aspirate using a 22G Jamshedi 85 
needle (CareFusion). BM aspirates of 10 ml were transferred to 5 ml of RPMI-1640 (Sigma) on 86 
ice. Additionally, a total of 50 ml of peripheral blood was obtained from the jugular vein into 87 
heparin sulphate containing tubes (BD Biosciences) for peripheral blood mononuclear cell 88 
isolation.  89 
 90 
Cell culture 91 
Bone marrow ovine mesenchymal stem cells (oMSCs) were isolated based on their adherence 92 
to tissue culture plastic (3). Bone marrow aspirates in RPMI-1640 were combined with an equal 93 
volume of alpha-MEM growth medium (Minimal Essential Medium alpha supplemented with 94 
10% fetal bovine serum (FBS) and 1% antibiotics (penicillin and streptomycin; Gibco)) before 95 
being seeded to a 75 cm2 tissue culture flask (Nunc) for 24 h and cultured in standard cell 96 
culture conditions at 37°C and 5% CO2 in air. The following day, media was discared and 97 
attached cells gently washed up to 10 times with pre-warmed phosphate buffered saline (PBS; 98 
Gibco) to remove non-adherent cells.  Flasks were incubated for a further 7 days in alpha-MEM 99 
with medium replaced every 48 hr to promote the emergence of colonies from adherent cells. 100 
Cells were detached from the flask by washing three times with pre-warmed PBS and 101 
incubating with %?? trypsin (Gibco) for 3-5 min with gentle agitation at what temperature??. 102 
Trypsin was inactivated with an equal volume of growth medium and cells recovered by 103 
centrifugation at 300 x g for 5 min. Isolated MSCs were re-suspended in growth medium and  104 
subsequently expanded at a seeding density of 1000 cells / cm2 in 175 cm2 tissue culture flasks 105 
(Nunc) for seven days and detached by trypsin treatment. Cells expanded at passage 2 were 106 
utilised for flow cytometry and trilineage analysis.  107 
Trilineage differentiation 108 
Trilineage differentiation was performed as previously reported (14), and briefly described here. 109 
Osteogenesis 110 
Osteogenic medium comprised Dulbecco's Modified Eagle's Medium (DMEM, low glucose) 111 
supplemented with 5 % FBS, 1 % antibiotics (all from Gibco), 10 nM dexamethasone (from), 5 112 
mM β-glycerolphosphate and 50 µM ascorbate (all from Sigma Aldrich). For osteogenic 113 
induction, MSCs were seeded in 6-well plates in triplicate at a density of 5,000 cells per cm2 in 114 
control and osteogenic medium for 21 days with bi-weekly medium changes. Cultures were 115 
washed and fixed in 2 % paraformaldehyde (Sigma Aldrich) for 20 min before being stained with 116 
a solution of 2 % Alizarin Red S in water, pH 4.3 (Sigma Aldrich).  117 
Adipogenesis 118 
Adipogenic medium comprised DMEM (low glucose; 1g/ml) supplemented with 10 % FBS, 1 % 119 
antibiotics (all Gibco), isobutyl methyl xanthine (IBMX), indomethacin and dexamethasone (all 120 
Sigma-Aldrich). Cells were cultured in 24 well plates in triplicate for control and adipogenic 121 
media with bi-weekly medium changes for 21 days. Cultures were then washed with PBS and 122 
fixed in 2 % paraformaldehyde for 20 min before staining with Oil Red O (Sigma) as described 123 
in (14).  124 
Chondrogenesis 125 
Chondrogenic differentiation was conducted according to previously described protocol (15). 126 
Approximately 2-3x105 cells in growth medium were pelleted by centrifuging at 400 x g for 5 min 127 
in 15 ml tubes (Nunc).  The cells pellets were then cultured in chondrogenic differentiation 128 
medium, which was composed of DMEM (high glucose) (Gibco) with 10% (v/v) ITS+ (BD 129 
Biosciences), 100 nM dexamethasone, 1 µM ascorbate-2-phosphate, 1 % sodium pyruvate and 130 
10 ng/ml TGF-β3 (R&D Systems). Pellets were maintained for 21 days with bi-weekly medium 131 
changes, and then fixed in 2 % paraformaldehyde before being processed for paraffin 132 
embedding and sectioned to stain with haematoxylin and eosin, alcian blue and saffranin-O as 133 
described previously (15). 134 
 135 
Comparison of reagents for cellular detachment  136 
A systematic comparison of cell detachment reagents was performed to identify the optimal 137 
conditions that yielded MSCs with homogeneous morphometric characteristics (forward and 138 
side scatter properties on the flow cytometer) while preserving the integrity of cell surface 139 
proteins for cross-reactive antibodies. The cellular detachment reagents tested were 0.25% 140 
Trypsin (Gibco); Accutase (StemPro); EDTA (what molarity?) in Hank's buffer (Gibco); a five 141 
part combination comprising 3 parts of Accutase and 2 parts of EDTA in Hank's buffer. Cultures 142 
of 1x106 MSCs (per 75 cm2 flask) (Nunc) were washed three times with pre-warmed PBS before 143 
incubating with 3 ml of each cell detachment reagent for 3-5 min in an incubator at 37°C. The 144 
reagents were then diluted with an equal volume of growth medium and detached cells 145 
transferred to 50 ml tubes (Falcon) tube for recovery by centrifugation at 300 x g for 5 min. In 146 
the case of EDTA, a cell scrapper (Falcon) was used to fully detach the cells.  Cell pellets were 147 
resuspended in 2 % paraformaldehyde for 30 min at room temperature.  This fixation step was 148 
aimed to minimise alteration in the expression levels of cell surface antigen after cell 149 
detachment and subsequent procedures.  The fixed cells were washed twice with PBS and 150 
centrifuged at 350 x g for 5 min before analysis by flow cytometery as detailed below. 151 
 152 
Single colour antibody staining 153 
The total mAbs tested are tabulated in Table 1. Fixed cell pellets were resuspended at a 154 
concentration of 3 × 106 cells in 1 ml of staining buffer that comprised PBS supplemented with 155 
10% FBS, sheep serum, goat serum (giving a final concentration of 30% serum) with 100 mg/ml 156 
bovine serum albumin (all from Sigma-Aldrich, Dorset, UK). Ovine peripheral blood 157 
mononuclear cells were isolated from systemic blood samples were used as controls to confirm 158 
cross-reactivity of antibodies that did not cross-react to oMSCs (Fig. 1, Supporting Information). 159 
All staining procedures were conducted in non-adherent round-bottom 96 well plates (Nunc). A 160 
100 µl volume of suspension containing 3x105 cells in staining buffer was transferred to each 161 
well in triplicate (??) for each antibody and for controls that consisted of an unstained and an 162 
isotype control antibody. Antibodies were used at the suppliers recommended dilutions. Sample 163 
incubation with antibody was performed with gentle agitation for 1 hr at room temperature 164 
protected from light. Samples were then transferred to polystyrene FACS tubes (Thermo 165 
Fischer) and washed twice by centrifugation at 350 x g for 5 min and re-suspending in 4 ml of 166 
PBS (Gibco). Cells were finally re-suspended in 250 µl of PBS and retained on ice protected 167 
from light untill analysis by flow cytometery.  168 
 169 
Multi-colour cell staining 170 
Multicolor staining was performed to confirm the co-localisation of cross-reactive antibodies on 171 
the same cell and to eliminate the possibility of staining by negative markers. A CD29-FITC 172 
mAB (green channel) was paired with CD271-Alexa 674 mAB (red channel) to evaluate co-173 
localisation of phycoerythrin (PE, yellow channel)-conjugated CD73, CD90, CD105 and CD166 174 
mAbs. The readings of single mAb stained MSCs were used for compensation calculations post 175 
hoc in flow cytometery analysis software FlowJo (Tree Star, OR) as described below.        176 
 177 
Flow cytometery  178 
Flow cytometry was performed on a BD FACS Calibur instrument (BD Bioscience, Cambridge, 179 
UK). The instrument was calibrated before each analysis with the CaliBRITE 3 FACS Comp 180 
beads (BD Biosciences) according to the manufacturer's instructions. For cellular analyses, 181 
unlabeled MSCs suspended in PBS in FACS tubes (12 × 75 mm2 BD Biosciences) were used 182 
to adjust the voltages and amps to position the population in the center of the scatter dot-plot 183 
based on forward and side scatter properties. Simultaneously, fluorescence channels were 184 
adjusted to place the unstained population within the first decade (order of magnitude) of the log 185 
intensity axis. Acquisition event counts was set for a total of 5 × 104 events. Sample cell 186 
suspensions were gently agitated before being analyzed at a low suction rate (60 μl/min). 187 
Further details are provided in MIFlowCyt (Supporting Information). 188 
Data analysis 189 
Sample data output generated from flow cytometry was analysed with FlowJo software version 190 
10.0.7 (Tree Star Inc). Gating was applied to exclude debris or multi cellular aggregates by 191 
selecting the central most population of single cells with highly similar morphologic and 192 
cytometeric characteristics. Isotype control readings were used against fluorescence readings to 193 
determine fluorescence shift. Outputs of positive and negative percentages from different 194 
experiments were combined to obtain a mean with standard deviation for positive and negative 195 
readings. Compensation was conducted post hoc with FlowJo using single stain analysis 196 
readings of mAbs. The resulting data was presented in 2 dimensional plots with quadrant 197 
percentages.      198 
 199 
Results 200 
Characterisation of bone marrow derived ovine MSCs 201 
A 10 ml aspirate of sheep bone marrow yielded ~2x105 plastic adherent cells after 7 days of 202 
primary culture. At this stage, these cells exhibited spindle shaped morphology (Fig. 1A) and 203 
were able to form colony forming units by 7–10 days when seeded at a limiting density (Fig. 1B). 204 
After further expansion, the oMSCs were capable of differentiating to adipogenic, osteogenic, 205 
and chondrogenic lineages (Figs. 1C–1F). 206 
 207 
Effects of cell detachment methods on ovine MSC scatter properties  208 
Data comparing forward and side scatter readings from different detachment reagents are 209 
presented as contour plots in figure 2. The cells detached with trypsin presented a single, 210 
morphometrically (size) and cytometerically (granularity) homogeneous population (Figure 2A).  211 
Cells detached with Accutase displayed a more dispersed scatter profile compared to trypsin 212 
with cellular aggregates appearing in the upper right corner of the scatter plot (figure 2 B). EDTA 213 
in Hank's buffer caused further heterogeneity as observed by the appearance of two 214 
morphometerically different but cytometerically similar populations (Figure 2C). This reagent 215 
also required a two-fold longer incubation time compared to the enzymatic methods and the 216 
need for total detachment encouraged by the use of a cell scraper in the case of fully confluent 217 
cultures. Furthermore, not all EDTA detached cells were spherical, but had retained their native 218 
spindle-shaped morphology (data not shown). The combination of Accutase and EDTA in 219 
Hank's buffer resulted in a scatter profile of oMSCs that was similar to that obtained with trypsin 220 
(Figure 2 D) but with less cell debris present. 221 
 222 
Single color flow cytometric analysis 223 
oMSCs were positive for CD73 (clone AD2; 96.9% ± 5.9), CD90 (99.6% ± 0.3), CD105 224 
(99.1 ± 1.5), CD271 (97.7 ± 2.0), and MHC1 (94.0% ± 7.2) (Fig. 3). In contrast, the oMSC 225 
populations were negative for mouse-antihuman CD117 (clone 104D2; 0.1% ± 0.1). Inconsistent 226 
low levels of cross-reactivity with other putative negative markers were observed: these were 227 
mouse-anti-sheep CD31 (clone CO.3E1D4; 14.6% ± 4.2); mouse- antisheep MHC class II (clone 228 
37.68; 10.5% ± 15.9); and mouse-antihuman CD45 (clone 1.11.32; 39.4% ± 31.8). 229 
 230 
 231 
Multi-color flow cytometeric analysis 232 
A single oMSC cell line prepared from a primary culture (not subjected to cell passage) was 233 
used to assess co-localisation of positive phenotypic markers. The results of this analysis are 234 
shown in figure 5. All positive markers evaluated in this experiment were observed to be co-235 
expressed on all gated cells. The negative markers CD34 and MHC Class II were not detected 236 
in these cells.   237 
Discussion 238 
This study has identified a panel of cross reactive monoclonal antibodies (mAbs) against cell 239 
surface markers (73, 90, 105, 271, MHC-I) on ovine mesenchymal stem cells (MSCs). In 240 
addition, antibodies cross-reactive to sheep CD31, CD34, CD45, CD117 and MHC-II were also 241 
identified for negative markers (<1% positive) of MSCs. The low expression of CD31 and MHC- 242 
Class II was encouraging in suggesting minimal contamination with white blood cells. These 243 
were positive against PBMCs but another white blood cell marker, using the mouse-antihuman 244 
CD34 (QBEND/10), was not observed to cause a significant shift against PBMCs, possibly due 245 
to confinement of the antigen to hematopoietic progenitor cells in bone marrow that were not 246 
tested here. Interestingly, a high expression of CD45 was detected in one of four primary cell 247 
cultures tested, which we speculate was due to unusually high contamination of cultures with 248 
adherent non-MSCs. 249 
Previous attempts at immunophenotyping ovine MSCs have been reported (13,16–18). These 250 
are based on negative selection criteria by using CD29 and CD44 as positive markers and 251 
CD31 and CD45 as negative markers, (18,19). Although this combination is sufficient in 252 
discriminating fibroblasts against hematopoietic cells, both CD29 and CD44 are not specific to 253 
MSCs, which significantly limits cellular identification by this method. In another report. In 254 
another report (17) the identities of the clones used to assess the wider range of positive 255 
markers were not provided, thus limiting wider use in sheep studies. This is particularly relevant 256 
to CD73 and CD105, whose clones displayed variable degrees of binding affinity in our study. 257 
For instance, the mouse-anti-human CD73-PE (clone AD2) was observed to cause lesser 258 
fluorescence intensity on the flow cytometer compared to the mouse-antirat CD73-PE (clone 259 
TY/23) in cells derived from the same primary culture, most likely due to lesser affinity to the 260 
antigen. Similarly, only one mAb against CD105 (rat-antimouse clone MJ7/18) out of four tested 261 
positively cross-reacted with oMSCs. In contrast, all four mAbs showed strong affinity to human 262 
MSCs. 263 
An important consideration to the expression of cell surface markers is the procedure used to 264 
detach cell from plastic.  Although trypsin provided morphometrically a highly homogeneous cell 265 
population, its replacement with a combination of Accutase and EDTA was also found to 266 
consistently yield populations of morphometrically homogeneous MSCs with good preservation 267 
of cell surface markers observed by flow cytometry. Importantly, however, it negated the 268 
possible harsher affects of trypsin on cell membrane proteins.  269 
The flow cytometery data also provides validation to the method of whole bone marrow plating 270 
for MSC isolation (3). Current techniques for the preparation of cell therapy products from bone 271 
marrow has employed density centrifugation or red blood cell lysis and recently, a convenient 272 
alternative in the form of direct plating of whole bone marrow for 24 hours followed by removal 273 
of debris and red blood cells to obtain adherent colony forming cells (3). While the latter method 274 
risks contamination by adherent non-MSCs, the findings presented here suggest this to 275 
minimally impact the population's characteristics as a whole.            276 
The panel of clones proposed in this study represent an important “tool-kit” to 277 
immunophenotypically characterise oMSC populations when investigating the effects of oMSCs 278 
in large animal models such as sheep. Our investigations would suggest that the best cell 279 
surface markers for defining oMSC populations should be CD90 and CD105 (>99% positive), 280 
CD73 and CD271 (>95%), while being <1% positive for CD117. 281 
  282 
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Table 1. Monoclonal antibodies tested against oMSCs 341 
Marker Antigen 
Antibody 
clone Host Reactivity 
Cross-
reactivity 
reported 
Catalogue identity and 
supplier 
Conjugated 
fluorochrome 
Cross Reactive mAbs 
CD29 Integrin, beta 1 MEM-101A Mouse Human No 
CD2901 Life 
Technologies FITC 
CD44a 
glycoprotein 
receptor for 
hyaluronic acid 25.32 Mouse Sheep 
Human, Goat, 
Cow MCA2219F Abdserotec FITC 
CD73 5'-nucleotidase TY/23 Mouse Rat No 550741 BD Biosciences PE 
CD90 
Thy-1 cell 
surface antigen 5E10 Mouse Human No 555593 BD Biosciences PE 
CD105 Endoglin MJ7/18 Rat Mouse No 562759 BD Biosciences PE 
CD166a 
Activated 
leukocyte cell 
adhesion 
molecule 3A6 Mouse Human No 559263 BD Biosciences PE 
CD271 
Neural Growth 
Factor receptor C40-1457 Mouse Human No 560877 BD Biosciences Alexa-Fluor® 647 
MHC-I 
Major 
Histocompatibili
ty Complex, 
Class I Bu8 Mouse Human No MCA2509F Abdserotec FITC 
MHC-II 
Major 
Histocompatibili
ty Complex, 
Class II 37.68 Mouse Sheep Bovine MCA2226F Abdserotec FITC 
CD31 
Platelet 
endothelial cell 
adhesion 
molecule type 1 CO.3E1D4 Mouse Sheep Bovine, Goat MCA1097F Abdserotec FITC 
CD45 
Lymphocyte 
Phosphatase-
Associated 
protein 1.11.32 Mouse Sheep 
Bovine, Goat, 
Dog MCA2220F Abdserotec FITC 
CD117 
Hematopoietic 
cell surface 
glycoprotein 104D2 Mouse Human No 
MCA1841PET 
Abdserotec RPE 
Non-Cross Reactive mAbs 
CD73 5'-nucleotidase AD2 Mouse Human No 550257 BD Biosciences PE 
CD105 Endoglin 43A3 Mouse Human No 
60039AD.1 Stem Cell 
Tech. Alexa Fluor® 488 
CD105 Endoglin SN6 Mouse Human Horse. 
MCA1557A488T 
Abdserotec FITC 
CD105 Endoglin 266 Mouse Human Horse. MCA1557FT Abdserotec FITC 
MHC-I 
Major 
Histocompatibili
ty Complex, 
Class I 2G5 Mouse Human Dog. MCA2189F Abdserotec FITC 
MHC-I 
Major 
Histocompatibili
ty Complex, 
Class I CVS22 Mouse Horse No 
MCA1086PE 
Abdserotec RPE 
MHC-II 
Major 
Histocompatibili
ty Complex, 
Class II 28.1 Mouse Sheep Bovine MCA2225F Abdserotec FITC 
CD34 
Hematopoietic 
Progenitor Cell 
Antigen QBEND/10 Mouse Human Monkey SFL547PE Abdserotec RPE 
Isotype controls 
Isotype 
control 
Anti-mouse 
IgG1: FITC with 
anti-rat IgG2a: 
RPE with anti-
rat IgG1: Alexa 
Fluor® 647  Mouse  No TC022; Abdserotec 
FITC/RPE/Alexa- 
Fluor® 647 
Isotype 
control 
Anti-mouse 
IgG1  Mouse  Rat MCA928F; Abdserotec FITC 
1. All mAbs used in this study are tabulated above. FITC, fluorescein isothiocyanate; RPE, R-phycoerythrin. 342 
a Reported previously by [13] to be cross-reactive against multipotent sheep MSCs.   343 
Figure legends / captions 344 
Figure 1 Characteristics of ovine mesenchymal stromal cells. (A) Early passage oMSCs with a 345 
fibroblastic spindle morphology. (B) The oMSCs formed single cell derived colonies when seeded at 346 
clonal densities (100 cells) in a 6 cm petri dish for 10-14 days. (C-D) Adipogenic differentiation assay 347 
showing positive Oil red O staining in induced samples. (E-F) Osteogenic differentiation assay 348 
indicating positive calcium specific Alizarin Red S staining in induced cultured. (G-I) Chondrogenic 349 
differentiation of oMSC shown in paraffin embedded sections with (top) hematoxylin and eosin, (centre) 350 
alcian blue stain for GAGs (centre) and (below) safranin-O GAG specific stain. 351 
 352 
  353 
Figure 2 . Comparison of cell detachment reagents. Contour plots at 5 % increments presenting the 354 
scatter profiles of cells detached from culture flasks with trypsin, Accutase, EDTA in Hank's buffer and 355 
a 3:2 mix of Accutase and EDTA. (A) Cells detached with trypsin exhibited a compact and 356 
homogeneous scatter profile. (B) Accutase derived cells displayed a relatively wider spread of cells 357 
than trypsin. (C) Cells detached with EDTA displayed  further heterogeneity by the appearance of two 358 
population of cells with equal cytoplasmic densities but differing sizes. (D) A 3:2 (v/v) combination of 359 
Accutase and EDTA resulted in a scatter profile of cells highly similar to trypsin with a characteristically 360 
compact and homogeneous profile. Furthermore, the quantity of larger aggregates or duplets confined 361 
to the top axis was less in the 3:2 mixture of Accutase and EDTA than these reagents alone.  362 
 363 
 364 
Figure 3. Single stain analysis of mAb cross-reactivity to human MSCs. (A) Forward and side scatter 365 
plot of human MSCs detached by the Accutase/EDTA combination. (B) Overlay of cells only (red) and 366 
isotype control labelled cells (blue). Reading obtained for different mAbs  (orange) are for (C) CD29, (D) 367 
CD44, (E) CD105 (clone 43A3), (F) mouse-human CD73 (clone AD2), (G) rat-mouse CD73 (clone 368 
TY/23), (H) mouse-human CD90 (clone 5E10) and mouse-human CD166.  369 
 370 
  371 
Figure 4. Multi-stain analysis of mAb cross-reactivity to oMSCs. (A) A contour plot based scatter profile 372 
of primary oMSCs. (B) Dual-stain analysis with CD29-FITC and CD271-Alexa 647 displaying co-373 
localization of the two markers on the oMSCs. This pair was used in triple stain analyses of samples to 374 
confirm colocalization with CD73 (C, D); CD90, (E, F); CD105 (G, H); CD166 (I, J). Additionally, a lack 375 
of costaining between CD271-Alexa 647 and MHC-II negative marker was seen in (K).  376 
 377 
